UBS Maintains Buy on Guardant Health, Raises Price Target to $225

Benzinga Newsdesk www.benzinga.com Positive 85.2%

Neg 0% Neu 0% Pos 85.2%

UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $175 to $225.

Comments

No comments yet. Be the first!